RecruitingRecruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
NCT07637110 · University of Washington
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This is a randomized trial of patients who are receiving in-center hemodialysis treatments for end stage kidney disease and have clinical suspicion of fluid overload. Enrolled participants will be randomly assigned in 1:1:1 fashion to either a four-week ultrafiltration strategy, an eight-week ultrafiltration strategy, or continuation of their regular thrice weekly hemodialysis treatments. Each ultrafiltration strategy will add two extra four-hour ultrafiltration treatments per week plus pharmacist-guided tapering of blood pressure medications. We will test the impact of these strategies on primary outcomes of
1. Change in 24-hour continuous ambulatory blood pressure from baseline to 24-weeks
2. Change in symptoms of congestion from baseline to 24-weeks We will also test the impact of the treatment strategies on related symptoms, physical activity levels, hemodynamics. and measures of safety.
Eligibility criteria
Inclusion Criteria:
* Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either:
1. Persistent hypertension defined by three consecutive pre-dialysis systolic blood pressures ≥140 mmHg or three consecutive pre-dialysis systolic blood pressures 130-140 mmHg plus use of at least two anti-hypertensive medications that can be tapered.
OR
2. Symptoms of congestion defined by a 12-item Kidney Modified Kansas City Cardiomyopathy Questionnaire (KM-KCCQ) score \<75.
Exclusion Criteria:
* Age \<18 years
* Receiving hemodialysis treatments for acute kidney injury
* Receiving hemodialysis treatments for less than four weeks
* Planned switch to peritoneal or home dialysis within next three months
* Current or planned incremental hemodialysis (less than 3 treatments per week)
* Current or planned intensive hemodialysis (four or more treatments per week)
* Scheduled kidney transplantation
* Major cardiovascular or bleeding event within previous 90 days
* Receiving chemotherapy or radiation treatment for cancer
* History of cirrhosis with ascites
* Inability to complete 24-hour ambulatory blood pressure measurement
* Wheelchair dependance or other inability to complete six-minute walk test
* Pre-dialysis systolic blood pressure \<100 mmHg
* Scheduled use of midodrine with hemodialysis treatments
* History of non-adherence with dialysis treatments
* Pregnancy
* Institutionalized
* Current or pending enrollment in hospice care
* Inappropriate for enrollment based on investigator or nephrologist discretion
Study design
Enrollment target: 120 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-10
Estimated completion: 2030-11
Last updated: 2026-10-30
Interventions
Procedure: Ultrafiltration
Primary outcomes
- • 24-hour continuous ambulatory blood pressure (Measurement performed at baseline compared to measurement performed at 24 weeks.)
- • Symptoms of congestion. (Questionnaire taken at Baseline compared the the questionnaire taken at 24 weeks.)
Sponsor
University of Washington · other
With: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contacts & investigators
ContactLuisa Rios-Avila · contact · lrios1@uw.edu · 206-258-9325
ContactErnest Ayers, MSPH · contact · ayerse@uw.edu · 206-685-1423
InvestigatorBryan Kestenbaum, MD, MS · principal_investigator, University of Washington
All locations (1)
Northwest Kidney CentersRecruiting
Seattle, Washington, United States